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This report describes the current state of flattening filter-free (FFF) radiotherapy
beams implemented on conventional linear accelerators, and is aimed primarily
at practicing medical physicists. The Therapy Emerging Technology Assessment
Work Group of the American Association of Physicists in Medicine (AAPM)
formed a writing group to assess FFF technology. The published literature on FFF
technology was reviewed, along with technical specifications provided by vendors.
Based on this information, supplemented by the clinical experience of the group
members, consensus guidelines and recommendations for implementation of FFF
technology were developed. Areas in need of further investigation were identified. Removing the flattening filter increases beam intensity, especially near the
central axis. Increased intensity reduces treatment time, especially for high-dose
stereotactic radiotherapy/radiosurgery (SRT/SRS). Furthermore, removing the flattening filter reduces out-of-field dose and improves beam modeling accuracy. FFF
beams are advantageous for small field (e.g., SRS) treatments and are appropriate
for intensity-modulated radiotherapy (IMRT). For conventional 3D radiotherapy
of large targets, FFF beams may be disadvantageous compared to flattened beams
because of the heterogeneity of FFF beam across the target (unless modulation is
employed). For any application, the nonflat beam characteristics and substantially
higher dose rates require consideration during the commissioning and quality
assurance processes relative to flattened beams, and the appropriate clinical use
of the technology needs to be identified. Consideration also needs to be given to
these unique characteristics when undertaking facility planning. Several areas still
warrant further research and development. Recommendations pertinent to FFF
technology, including acceptance testing, commissioning, quality assurance, radiation safety, and facility planning, are presented. Examples of clinical applications
are provided. Several of the areas in which future research and development are
needed are also indicated.
PACS number: 87.53.-j, 87.53.Bn, 87.53.Ly, 87.55.-x, 87.55.N-, 87.56.bc
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I.

INTRODUCTION

Photon beams are generated by bombarding a high-Z target with a high-energy electron beam.
The resultant megavoltage bremsstrahlung beams present a bell-shape profile with the highest intensity at the center. In conventional linear accelerators, uniform intensity across the
treatment field (at least nominally) is obtained by placement of a flattening filter in the beam.
However, modern radiotherapy practice now routinely utilizes fluence modifying techniques,
such as intensity-modulated radiation therapy (IMRT), to create more conformal dose distributions. In such cases, the flattening filter becomes unnecessary in the beam production process.
Additionally, for small fields (such as are used in stereotactic procedures), even without the
flattening filter the treatment field is nearly flat over the central few centimeters, again rendering
the flattening filter unnecessary; furthermore, as neither patients nor targets are flat, flattening
filter-free (FFF) fields may be useful for moderate or even large targets.
Clinical use of FFF beams was initially driven by the attempt to reduce the long delivery time
required for SRS treatments, as removing the flattening filter increases the dose rate by a factor
of 2–4. The increased intensity associated with FFF beams is particularly useful for small field
stereotactic radiosurgery (SRS) and/or stereotactic body radiation therapy (SBRT) procedures,(1)
but may be useful for a wide range of fields and treatments.(2,3) Other early clinical applications
were also reported using FFF technology to improve the delivery efficiency,(4-6) evolving into
studies of stereotactic body radiation therapy (SBRT),(7-10) all of which demonstrated positive
results. FFF technology has been in clinical use for many years, starting with the Scanditronix
racetrack microtron MM50.(11,12) More modern linear accelerators that omit the flattening filter
include the helical TomoTherapy machine, as well as CyberKnife system.(13-15) It is, therefore,
no surprise that mainstream linear accelerators now include this as standard product offering.
FFF beams have many distinct characteristics compared to conventional photon beams.
They have a different beam profile and higher dose rate, but also a different photon energy
spectrum and different head-scatter properties. Consequently, there are unique features to FFF
beams, including properties of the beams (sharper penumbra, less head scatter, and less outof-field dose), dosimeter response (increased ion recombination), vault shielding, and possibly
even radiobiology. At present, hundreds of medical linear accelerators with FFF functionality
have been installed. However, general guidelines regarding the acceptance, commissioning,
and quality assurance have not been compiled. This document provides a technical overview
of current FFF technology, and offers guidelines and recommendations for dose-calculation,
acceptance testing, commissioning, quality assurance, facility planning, radiation safety, and
clinical implementation.
II. TECHNICAL ISSUES
A. Machine Overview
There are multiple commercial implementations of FFF technology now available and a review
of the treatment head physics including monitor chamber and steering effects, X-ray spectra,
photon and electron characteristics, and neutron production has recently been published.(16,17)
The following sections supplement this work by providing technical summaries of commercial
systems available at the time of this report.
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A.1 Varian
Varian Medical Systems offers 6 and 10 MV FFF beams on the TrueBeam linear accelerator, in
addition to the conventional flattened beams. Varian refers to the FFF beams as “High Intensity
Mode.” Beam characteristics are presented in Table 1. In their implementation, the same electron
beam is used to create both flattened and FFF beams of the same nominal energy. Therefore,
electron energy at the target is the same and removal of the flattening filter increases output, but
also reduces the penetrative quality of the photon beam due to the reduced beam hardening.
Both the 6 and 10 MV FFF beams use a tungsten target. On FFF machines, the carousel that
holds the flattening filters also has a position containing a 0.8 mm thick brass plate that is used
for the FFF beams in place of a flattening filter to filter electrons and low-energy photons.(18)
The monitor chamber is comprised of two separately sealed, positive-pressure chambers.
Whereas the traditional C-series linac had four sectors per chamber, the TrueBeam accelerator
includes a fifth, central, sector that evaluates coarse flatness. The primary chamber monitors
dose rate and radial profile shape. The secondary chamber monitors dose rate and transverse
profile shape. The beam monitoring system digitizes and counts every beam pulse and generates corrective feedback to beam steering servo systems to control the profile shape. For FFF
beams, symmetry is actively controlled by the beam steering systems.
Table 1. Characteristics of commercially available FFF beams. All dosimetric quantities are given for a 10 × 10 cm2
field at 100 cm SSD unless otherwise noted and were provided by the manufacturers.
Varian
Nominal energy (MV)

6 FFF

Bremsstrahlung target material
Approximate mean electron
energy on target (MeV)

10 FFF

Tungsten
6.2

10.5

Elekta
6 FFF

Siemens

10 FFF

7

10.5

14 UF

17 UF

Tungsten
8.9

2mm Stainless steel

14.4

16.4

18.3

Filtration

0.8 mm Brass
1.5

2.3

1.7

2.4

1.9

2.7

3.0

3.3

Dose at 10 cm depth (%)

64.2

71.7

67.5

73.0

68.5

74.5

76.5

78.0

59a

68

57

-

-

2200

2000

2000

2000

2000

0.13

0.13

0.13

0.13

77

60

70a

Maximum dose rate on beam
axis at dmax (cGy/min)

1400

2400

1400

Dose per pulse on beam axis
at dmax (cGy/pulse)

0.08

0.13

0.06 0.09/0.14b

b

11 UF

dmax (cm)
Dose 10 cm from central axis
(40×40 cm2 field), at dmax (%)

a

7 UF

Tungsten

1.27 mm Al

Defined at 90 cm SSD, 10 cm depth
Feedback/nonfeedback machine.

A.2 Elekta
Elekta offers 6 and 10 MV FFF beams on the Versa HD linear accelerator, in addition to the
conventional flattened beams. Elekta refers to the FFF beams as “High Dose Rate Mode”
(characteristics presented in Table 1).
In contrast to the Varian linear accelerator, the same electron beam is not used to create the
FFF and corresponding flattened beam. Each of the beams on the Elekta family of linacs is
defined by its own independent set of parameter values, referred to as its ‘Energy Set’. Each
Energy Set includes the radio frequency and gun settings that define the electron beam energy
and also the dosimetry calibration settings. Each of the FFF energies has its own independent
Energy Set different from any flattened beam. This allows the penetrative quality of the FFF
beams to be restored to the nominal value for that energy.
In the linac head, the bremsstrahlung beam is filtered with a stainless steel disc instead of the
usual flattening filter. In addition to removing low-energy photons, this also produces electrons
Journal of Applied Clinical Medical Physics, Vol. 16, No. 3, 2015
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that provide signal to the ion chambers in the treatment head that measure dose and other beam
parameters. Two ion chambers provide independent measurements of dose, and a third contains
a set of six collection plates arranged geometrically to provide uniformity signals for use by
the beam control servo system that ensures beam stability.
A.3 Siemens
Although no longer in the radiotherapy market, many Siemens FFF machines are in clinical use,
and so their properties are discussed here. Siemens offers a high-intensity unflat (UF) beam in four
photon energies: 7 UF, 11 UF, 14 UF, and 17 UF, in addition to the conventional flattened beams.
At the time of this report, Siemens is the only manufacturer that offers a high-energy (> 10 MV)
FFF beam. Available properties of the Siemens FFF beams are presented in Table 1.
Similar to the Elekta linac, the electron energy at the target for the FFF beams is different
from the corresponding flattened beam; the 7 UF beam has a different accelerating potential
than the flattened 6 MV beam (selected to result in a similar depth-dose curve). Nomenclature
for the FFF energies was also selected in an effort to minimize the accidental use of an FFF
beam in place of a flattened beam. For example, 11 MV UF would be distinct from 10 MV
flattened, although the two beams may have very similar radiological characteristics on the
central beam axis.
Two sealed dose chambers, named Monitor_1 and Monitor_2 perform photon dosimetry
in Siemens linacs. The function of dose Monitor_1 is to measure each dose pulse. Monitor_2
consists of five chambers that are used for measuring each dose pulse (redundant to Monitor_1)
and monitoring off-axis characteristics.(17)
B. Acceptance testing
Acceptance testing for a linear accelerator without a flattening filter is similar to that of a
conventional linear accelerator. The guidelines described in AAPM TG-45(19) and TG-142(20)
reports should be followed, with the sole exception relating to the testing of those properties
related to the beam flatness. Instead of measuring the flatness, the shape of the beam profile
must be verified to ensure that it meets the machine performance specifications provided by
the manufacturer. The details of these specifications, such as the number and location of profile
points to be checked, are dependent on the agreement between the hospital and manufacturer
at the time of purchase; however, specifications for beam profile shape should not vary substantially between flattened and FFF beams. Beam shape and symmetry measurements will
typically be obtained using either a scanning system in water or film.(19) Because of the higher
dose per pulse of FFF beams, dose rate dependent measurement devices should be evaluated
for possible effects, as described in sections C.1 and C.2.
C. Commissioning
C.1 Calibration
A standard calibration protocol, such as TG-51(21) or TRS-398,(22) should be followed. With
the removal of the flattening filter, four special considerations, detailed below, exist due to differences in the beam quality, dose per pulse, and profile shape. These issues are also addressed
in the AAPM Working Group on TG-51 report.(23)
First, for a Varian implementation of the FFF beams, the softer photon spectrum results in a
different beam quality conversion factor, kQ, than was used for flattened beams. More generally,
because of the different photon spectrum for any FFF beam, the beam-quality specifier for a
FFF beam, as compared with a flattened beam, has a different relationship with Spencer-Attix
stopping-power ratios.(24) However, the standard relationship between %dd(10)x and the ratio
of (L/ρ)air to (L/ρ)water, which is used in the TG–51 protocol to calculate the quality conversion
factor kQ, is acceptable for beams with or without a flattening filter with a maximum error of
0.4%. That is, kQ may be slightly different for FFF beams, but can be determined in the same
Journal of Applied Clinical Medical Physics, Vol. 16, No. 3, 2015
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manner as was done for flattened beams. It is also important to note that the validity of this
method to determine kQ only applies to chambers with low-Z or aluminum electrodes; chambers with high-Z electrodes should not be used for reference dosimetry in FFF beams.(23,25)
As an alternative approach to specifying beam quality, studies have also evaluated using
TPR10/20.(26) It was found that, if TPR10/20 is used, there are two different relationships
between the ratio of (L/ρ)air to (L/ρ)water which differ by 0.4%–1%. When using TPR10/20 in a
beam without a flattening filter, it is necessary to subtract 0.5% from the value of kQ for a given
value of TPR10/20.(27) Due to this complication, this method should be used with caution.
Second, it is recommended in TG-51(21) that, when determining kQ at high energies (about
10 MV and above), 1 mm of lead be used to reduce electron contamination at dmax to a negligible
level. It is unclear if FFF beams at 10 MV require the use of lead. The prudent and appropriate
approach is to use lead unless it has been verified to be unnecessary for a given beam (that is,
the same value of kQ is produced).
Third, the elevated dose per pulse of FFF beams results in increased ion recombination and
therefore a larger correction factor, Pion.(28,29) However, it is likely that Pion can be calculated
using the same two-voltage formalism that is presented in TG-51 for flattened beams — this
approach was found to be accurate within 0.3% for common Farmer-type chambers, and offers
comparable accuracy to that seen for flattened beams.(28) However, per the AAPM Working
Group on TG-51 report, the suitability of the two-voltage technique should be verified for
all reference dosimetry scenarios, including FFF (and flattened) beams.(23) This can be done
through the use of Jaffe plots (1/current (or charge) vs. 1/voltage) to determine the relationship
between the ionization chamber bias and signal lost to recombination and, therefore, the validity
of the two-voltage Pion. The correction factors of several commonly used ionization chambers
for Varian 6 MV and 10 MV FFF beams are shown in Table 2. Of note, Pion is determined
primarily by the instantaneous dose rate (the dose per pulse), which usually doesn’t change
with changes to the nominal dose rate of the linac. Therefore, changing the nominal dose rate
cannot be used to verify or evaluate the dose-rate dependence of a dosimeter or its suitability
in the high-dose-rate environment of an FFF beam.
Fourth, because the radiation profile is peaked on the central axis, large volume Farmer-type
ion chambers placed on the central axis will experience some partial volume averaging, and
therefore underestimate the dose on the central axis. This effect was examined for Varian 6 and
10 MV FFF beams based on film-measured profiles in Kry et al.(28) Based on the dose falloff
away from the central axis and the dimensions of Farmer-type chambers, a partial volume effect
was estimated to be 0.2% for both energies — that is, the ion chamber measurement would
be 0.2% less than the true dose on central axis. This effect would be slightly larger if the ion
chamber was not centered in the radiation field or if the beam was not properly steered. If the
chamber was offset 5 mm from isocenter along the direction of the chamber (maximizing the
size of the effect), the dose could be underestimated by up to 0.3% relative to the central-axis
measurements (for a 10 MV FFF beam).(28) Partial volume effects and setup sensitivity would
also be more pronounced at higher energies, at penumbra regions, or at regions of the profile
with sharper dose falloff. Reasonable care should be used when centering the ion chamber. The
AAPM Working Group on TG-51 report recommends correction of the partial volume effect and/
or the use of chambers with a short collecting volume to minimize partial volume effects.(23)
Table 2. Examples of measured Pion values at 300 V for Varian flattening filter-free (FFF) beams at 10 cm depth in
water and at dmax with three different ion chambers.(28)
6 MV FFF
Chamber
Exradin A-12
PTW TN30013
NEL 2571

10 cm
1.006
1.005
1.008

10 MV FFF
dmax
1.009
1.008
1.013
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C.2 Profiles, depth doses, and other dosimetric properties
Commissioning and measurements of dosimetric properties should follow the general recommendations from TG 106,(30) which contains detailed specification as to the scanning and nonscanning data measurement requirements. A number of reports have descriptions of successful
commissioning of FFF beams for various energies.(2,3,31-33)
For scanning measurements with an ion chamber, the variation in dose per pulse with
depth and across the beam profile results in Pion varying with off-axis position and depth (e.g.,
Table 2). The magnitude of the effect is dependent on variations in dose per pulse, as well as
the chamber design (particularly the electrode spacing). While recombination, and therefore
variations in recombination, will often be smaller for smaller scanning chambers, this may not
always be the case. Changes in Pion would be expected to be less than 1% for many scanning
chambers based on Table 2 data and other investigations.(34) However, for a given model of
scanning chamber, the range of ion recombination should be measured — between dmax on the
central axis (maximum dose per pulse) and at a relatively deep depth far off-axis (minimum
dose per pulse). Clinical judgment should then be used to determine if the variation in Pion is
acceptable. If it is not acceptable, a different chamber or dosimeter should be used. For flattened beams, Pion also changes as a function of depth (or with wedges, for example). However,
changes in Pion are not generally accounted for because Pion is very close to 1 and therefore
variations in Pion are very small. For FFF beams Pion is larger, and therefore variations in Pion
across the treatment field will be larger.
Dose-rate effects may be relevant to other dosimeters, as well, and careful attention should
be paid to any dose-rate-dependent device.
The commissioning scans of FFF beams will have different characteristics than are seen
with flattened beams. The type and magnitude of these differences will depend on whether
the energy of the electrons hitting the bremsstrahlung target has been increased (to restore the
PDD), as with Elekta linacs, or not, as with Varian linacs. It should be noted that restoration of
the PDD does not equate to equivalence of the underlying spectra and, while other properties
may often be similar, they should not be expected to be identical. Below are presented major
characteristics and the results that should be expected for FFF beams.
The PDD will be more shallow for FFF beams because the photon energy spectra are softer,
unless the PDD has been restored through increasing the electron energy.(2,35) However, for
all FFF beams, the PDD has minimal dependence on off-axis position and, therefore, while
the beam profile will show a bell-shape, the shape of the profile will change only minimally
with depth (off-axis factors are minimally depth dependent).(2,35,36) In flattened beams, profile
shape varies with depth primarily because of spatially variant beam-hardening, which does not
occur for FFF beams.
Machine output measurements show less variation with field size for FFF beams than for
conventional flattened beams. This was demonstrated by Vassiliev et al.(2) who measured Sc,p
for a range of field sizes. The decreased variability in output is attributed to decreased head
scatter because the absence of the flattening filter removes a major scatter source.(37) Naturally,
phantom scatter factors are also different than for flattened beams.(32)
The penumbra for FFF beams has been found to be sharper than for flattened beams (particularly for small fields), although this is most clearly the case when the energy of the FFF
beam was not raised (to restore the PDD).(32,38) When the energy was raised (as for Siemens
and Elekta linacs), the FFF penumbra has been found to be comparable to, or broader than, the
penumbra for flattened beams.(32,32) In general however, these differences are small.
When the energy has not been restored, the softer photon spectrum results in less MLC leaf
transmission.(32,38)
For a Varian linac, skin dose for FFF beams has been found to be modestly higher compared
to flattened beams, as measured with a parallel plate ionization chamber.(23,39) For example, the
dose at 1 mm depth relative to Dmax was found to be 53% for a flattened 6 MV beam, but 61%
for an FFF beam. Skin dose varies with field size; because there is less low-energy contamination
Journal of Applied Clinical Medical Physics, Vol. 16, No. 3, 2015
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from head scatter, skin dose from FFF beams increases more slowly than for FF beams as field
size increases. Consequently, skin doses from FFF beams may be comparable or even lower
than for flattened beams for large fields.(3,32) Increasing the beam energy to restore the flattened
PDD mitigates the increase in skin dose.(32) In general however, further study of surface doses
is warranted to more fully understand the impact of treatment parameters, the skin dose associated with clinical treatment conditions, and the reliability of the TPS in predicting skin dose in
the plans for which FFF might be used. While several studies in the literature have estimated
the skin dose, this has typically been at a depth of 3 mm, which generates substantially different doses than at the actual depth of the skin target cells (≤ 0.1 mm(40,41)). Because skin dose
measurements are difficult to make and treatment planning systems don’t model this region
accurately, we therefore recommend choosing beam arrangements that distribute the entrance
dose over multiple ports, as is always good clinical practice.
Outside the treatment field, FFF beams generally produce lower dose.(1,32,42-44) Leakage radiation and collimator scatter are substantially reduced. However, patient scatter is not decreased
in the presence of a softer primary photon beam.(42) Doses outside the treatment field are most
reduced in FFF mode for smaller or highly modulated fields, such as stereotactic treatments, as
head leakage is relatively important for these treatments.(1,32) When the energy of the electrons
striking the target is increased (to restore the PDD as in the Elekta and Siemens implementations), the out-of-field dose is lower than when the electron energy is left unchanged.(44)
C.3 End-to-end testing
Task Group 142(20) recommends end-to-end testing anytime new procedures are introduced.
End-to-end testing helps ensure the safe operation of the entire system, including the treatment
planning system, the R&V system, and the delivery system. For flattening filter-free beams,
areas of concern include accurate modeling of the flattening filter-free beam by the TPS and
proper transfer of the treatment plan to the delivery system, particularly the novel feature of
the FFF beam designation. The current DICOM standard does not explicitly handle FFF beams
and so vendors have adopted different schemes for encoding the FFF property. An end-to-end
test, comprised of a CT scan of a phantom, transfer of the CT images to the TPS, generation
of a clinical plan, transfer of the plan to the R&V system, and delivery of the plan, is therefore
critical. The end-to-end test should follow the clinical process completely, handling the phantom
in the same manner as a patient. This should also examine mixing conventional and FFF beams.
At a minimum, point measurements should be made to verify the correct dose. An excellent
resource for IMRT and VMAT end-to-end testing is the report of Task Group 119.(45)
D. Periodic quality assurance
Development of a periodic quality assurance program is ultimately the responsibility of the
site physicist, but must conform to applicable regulations, and should generally follow professional guidance documents, such as Task Group 142,(20) although other established standards
may also be acceptable.
Most QA procedures for FFF beams and linear accelerators are consistent with the QA that
should be performed for traditional flattened beams. The vast majority of mechanical, safety,
and even dosimetric properties of FFF beams and delivery systems are the same as for flattened
beams, and the QA program can therefore largely follow traditional QA. Regarding the shape of
the beam profile, TG-142(20) can be followed directly, establishing the “baseline” beam profile
shape during commissioning. The profile shape can then be evaluated against this baseline on
a point-by-point or area comparison basis (as is done for flattened beams), or by evaluating
the slope of the profiles.(46) However it is assessed, and similar to other FFF beams such as
TomoTherapy,(47) the consistency of the profile should be verified monthly (although more
frequently may be easily achievable with some daily QA devices). The shape of the profile
should also be compared to the treatment planning system data annually.
Journal of Applied Clinical Medical Physics, Vol. 16, No. 3, 2015
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E. Treatment planning
E.1 Planning systems
Modern treatment planning systems employ model-based algorithms for dose calculation.
Model-based algorithms should be able to accommodate FFF beams; indeed the radially uniform
FFF photon energy spectrum has been found to make modeling of such beams more accurate
than the modeling of flattened beams.(48) However, the specific software implementation must
be designed to handle FFF beams, and the TPS vendor’s instructions must specify the necessary
beam data. Various commercial treatment planning systems are reported to have the capability
to accurately handle FFF beams, including the Eclipse analytical anisotropic algorithm (Varian
Medical Systems),(49) Eclipse Acuros XB (Varian Medical Systems),(49) Pinnacle collapsed cone
convolution superposition (Phillips),(31) CMS XiO (Elekta),(31) Oncentra MasterPlan enhanced
collapsed cone convolution (Elekta),(48) Monaco Monte Carlo (Elekta),(48) and Prowess Panther
(Prowess Inc.).(50) Other vendors should be consulted to determine the status of their support
for FFF beams. The commissioning of FFF beams for treatment planning systems should follow standard guidelines.(45,51)
E.2 Planning, optimization
For conventional treatment planning or forward treatment planning, the use of FFF beams may
be more challenging than using conventional flattened beams because of the nonuniform intensity
across the field. However, this difficulty is mitigated for small fields as intensity variations are
minimal over the central 1–2 centimeters of the treatment field.(2) In general, neither patients
nor tumors are flat; target coverage with FFF beams is readily achievable for small targets and
may be achievable for larger targets, as well. Unmodulated FFF beams have been found to be
suitable for small-field procedures, such as SRS/SBRT, using 3D CRT.(1,52) FFF modalities
should also be suitable for forward planned IMRT (e.g., field-in-field technique); however, as
field size increases, forward planning may become more challenging. In general, FFF beams
are not used for large, unmodulated fields.
Computer optimization, as used in inverse planning, removes the challenges of the nonuniform fluence. During IMRT planning, a typical broad beam is divided into many small beamlets
to provide sufficient freedom of beam intensity variations required for IMRT. FFF beams have
inherent intensity variations, but these are directly incorporated into the IMRT plan optimization.
Several authors report that IMRT plan qualities are comparable when based on either flattened
or FFF beams.(31,53,54) FFF beams may sometimes produce slightly better target conformality
and/or critical structure sparing,(53) but mixed results have also been reported across different
disease sites and with different energies.(55) Consistently though, the differences have been
found to be small and likely not clinically significant. Other treatment plan characteristics also
change with the use of FFF beams. With FFF beams, it was found that more segments were
required compared to IMRT plans with flattened beams for nonconcave tumor volumes and for
large tumor volumes, although for small tumor volumes or highly concave tumor shapes, the
number of segments in IMRT plans with FFF versus flattened beams were similar.(54) Finally,
FFF beams also require more monitor units to deliver treatments as, for off-axis points, less
than 1 cGy is delivered per MU.
It must be noted though that the specifics of 1 MU is different between flattened and FFF
beams. One MU corresponds in both cases to the signal measured in the monitor chamber that
corresponds to a dose of 1 cGy under reference conditions. However, for FFF beams, much less
target current is required to produce the same signal in the monitor chamber. Correspondingly,
less target current is required to deliver 1 MU, and less target current is required to deliver a
course of treatment,(56) even though more MUs are required.
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III. CLINICAL ISSUES
A. Treatment plans and delivery
FFF beams have been implemented and evaluated for various disease sites. The main comparisons
are based on delivery time and dosimetry. The increased dose rate allows for faster delivery, which
may reduce the effects of patient and/or target motion, and increase patient comfort. The shortened
delivery time will benefit some motion control techniques, such as breath-hold. Treatments of
small-sized tumors benefit most as they have the most elevated dose rate. Dosimetrically, the
quality of both stereotactic and IMRT treatment plans with FFF delivery is comparable to that
using flattened beams. Dosimetric equivalence is not a surprising finding, given the long history
of use and good performance of FFF beams in devices such as TomoTherapy.(57,58)
Studies have also typically found that IMRT treatment planning time is independent of
whether or not a flattening filter is in place.(59,60)
B. SRS/SBRT applications
The FFF modality was first investigated by O’Brien et al.(1) for radiosurgery applications.
More recently, and with a modern linac, Vassiliev et al.(52) assessed the feasibility of stereotactic radiotherapy for early stage lung cancer using FFF photon beams from a Varian Clinac.
Flattened beam 3D CRT treatments for 10 clinical patients were replanned with FFF beams.
This study found that dose homogeneity in the target was not significantly different between
treatments using flattened or FFF beams (p = 0.3), and that doses to critical structures were
comparable. The median beam-on time per field was reduced from 25 s (with the filter) to
11 s (without the filter), increasing the feasibility of breath-hold treatments and the efficiency
of gated treatments. On a clinical machine, Gasic et al.(55) evaluated 30 SRS/SBRT patients
for FFF versus flattened VMAT. They similarly found negligible dosimetric differences, but a
reduction in beam on time of 50%–75%. Prendergast et al.(8) also highlighted the substantial
time advantage of FFF beams for stereotactic treatments with a review of 27 CNS radiosurgery
cases treated using FFF beams. Delivered doses ranged from 12 to 30 Gy, delivered in 1 to 5
fractions. Despite the large dose per fraction, the mean time the patient spent in the treatment
room (from the beginning of imaging to the completion of treatment) was only 10:42 (min:s;
range: 6:05–22:56), leading to the conclusion that single fraction and hypofractionated CNS
SRS can be accomplished within a standard radiotherapy time slot.
On a more cautionary note, however, Ong et al.(61) found that the faster delivery may
accentuate interplay between breathing motion and leaf motion, which may be a concern in
hypofractionated IMRT in the thorax and abdomen.
C. IMRT applications
Numerous studies have evaluated the potential for FFF beams to deliver IMRT. Fu et al.(54) first
considered this, exploring treatment delivery time, and found that FFF plans require up to 50%
less beam-on time than corresponding flattened beam treatments based on IMRT of the head
and neck and prostate. This reduction was not clinically significant with 2 Gy doses, although
it could be for larger doses per fraction.(54) Vassiliev et al.(53) compared treatment plan quality
for flattened beam versus FFF IMRT of the prostate at 6 and 18 MV with a Varian linac and
the Eclipse treatment planning system. Similar work was also done by Stathakis et al.(31) using
Pinnacle’s collapsed cone convolution superposition algorithm. Both groups found comparable
plan quality regardless of the presence of the flattening filter, with no clinically significant difference in terms of organ at risk doses and target dose homogeneity.
Stathakis et al.(31) also evaluated head and neck, brain, and lung treatments using flattened
versus FFF 6 MV IMRT. Again, minimal differences were seen between the beams in terms
of target coverage, target homogeneity, or organ at risk DVH values. Spruijt et al.(62) evaluated breast therapy using FFF beams and also found comparable dosimetric results between
flattened and FFF beams.
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FFF beams can be used in conjunction with VMAT delivery techniques. Zwahlen et al.(22)
compared VMAT plans for the prostate using 6 MV and 10 MV flattened and FFF beams. All
four beams delivered comparable dosimetric plan quality. Treatment time was reduced by 35%
when a single arc was used, but there was no difference in treatment time when multiple arcs
were used (as the linac always rotated at maximum speed). However, even for the single-arc
case, the reduction was only from 1.5 min to 1 min, reinforcing the findings of Fu et al.(54) that
the delivery efficiency advantage for FFF beams at conventional fraction sizes is small and not
of clinical significance. Similar results were found by Subramaniam et al.(63) who evaluated
VMAT for the chest wall, by Nicolini et al.(64) who evaluated VMAT for the esophagus, and by
Gasic et al.(55) who evaluated VMAT for the brain, prostate, and head and neck. All three studies found comparable dosimetric results between the flattened and FFF beams; Subramaniam
et al.(63) found some improved sparing of organs at risk with FFF beams, Nicolini et al.(64) found
a small increase in delivery efficiency with FFF beams, while Gasic et al.(55) found reduced
homogeneity in the target for FFF beams in the brain and head and neck.
D. Treatment delivery verification
Verification of FFF planned doses has been conducted, typically in the form of IMRT QA.
Stathakis et al.(31) measured the dose distributions in an acrylic phantom using a PTW 0.125 cc
ionization chamber and Kodak EDR2 film. The point dose measurements were within ± 3%
and planar film analysis showed reasonable agreement under qualitative evaluation. Salter
et al.(50) evaluated seven plans using the Delta4 device (ScandiDos) and found central axis
dose agreement within 3%, and greater than 95% of pixels passing gamma (3%/3 mm). A
multi-institutional study analyzed QA results for 224 patients treated using FFF beams, using
both static field IMRT and arc techniques, and found them within the specified limits of 3 mm
distance to agreement and 3% dose difference. This study was notable in that four verification
devices were used and only small variations were found among the devices.(65) These findings
are an important step for evaluating QA devices, as “inaccuracy of QA devices” was a substantial concern in the FMEA analysis (see Table 3 in section III.G). Before use, clinical physicists
should be thorough in evaluating the dose-rate characteristics of their QA devices, and analyze
their passing behavior when using them for FFF beams. This can be done using a combination
of literature review, vendor specifications, and direct measurement.
E. Limitations of FFF
The addition of FFF beams to modern linear accelerators requires additional commissioning
and routine quality assurance. The Varian TrueBeam, for example, offers up to five clinical
photon beams. The addition of FFF beams raises the question: “How many beams are needed to
deliver high-quality care while not overwhelming QA resources?” Could FFF beams completely
replace conventional flattened beams, which would then prevent a large increase in the number
of clinical photon beams maintained? There are some limitations to this idea:
1. To replace conventional flattened beams with FFF beams in situations where 3D conformal
radiation therapy is appropriate generally requires intensity modulation of the FFF beam. For
example, wedged or gently modulated fields are often used with flattened beams for whole
breast therapy. While FFF beams can generate acceptable plans for the whole breast,(62) beam
modulation is generally required. At many institutions in the US, IMRT for breast would
require a change in clinical practice with associated billing implications.
2. In situations where short planning time is important, such as palliative cases, flattened beam
plans can be planned and delivered much faster than inverse plans.
3. There are many clinical situations, particularly in the treatment of deep tumors, where highenergy beams are preferred to 6 or 10 MV beams. On most platforms, high-energy FFF
beams are not available.
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4. Total body irradiation (TBI) treatments and other extended distance treatments, such as
mantle fields and spinal fields for craniospinal fields, are generally made more complicated
with FFF beams.
These issues could be addressed in a number of ways, such as including an internal optimization option to generate a flat beam profile, or the availability of high-energy FFF beams.
However, such options are not currently available, indicating value in maintaining at least one
conventional flattened beam.
F. Practical considerations
Implementation of FFF technology requires some special considerations, including: 1) dosimetric understanding of the technology; 2) the effective use of the technology; 3) requirement
of resources to implement the technology; and 4) quality assurance and safety.
As part of commissioning, the clinical workflow of how FFF will be implemented should be
carefully understood and documented for each step of treatment: immobilization, simulation,
planning, localization, and delivery.
Since FFF technology is relative new, beam characteristics need to be carefully studied prior
to clinical use. Suitable measurement devices are available, but may require new equipment
purchases and extra resources and training of the staff to perform these tasks. Clinical application procedures and quality assurance procedures should be developed as early as possible.
More importantly, the site should develop protocols about what kind of patient and treatment
will fit the FFF technology. Since not every patient and every type of treatment will be suitable for FFF technology, each clinical site should develop protocols about the criteria for using
FFF technology. For example, when it can be used for treatment techniques such as 3D CRT,
IMRT, and VMAT, and when it can be used for treatment procedures such as SRS and SBRT.
G. Safety considerations
There are unique safety considerations or “failure modes” that are particular to FFF, and therefore should receive additional attention to proactively examine special risks introduced by FFF,
at least while this technology matures. While these failure modes and potential risks are not
fully understood at this time, they include concerns with dosimetry and calibration, but also
clinical workflow. Failure Modes and Effects Analysis (FMEA) has been suggested as a useful
risk assessment method, with several FMEA evaluations published, and as recommended by
TG-100.(66-72) The type and frequency of QA tests should depend on the likelihood of failure
(O), the severity of the consequences if something goes wrong (S), and the detectability of the
failure (D). The TG members have done the FMEA in Table 3 for new risks resulting from the
introduction of FFF to an established clinical practice, but readers are encouraged to evaluate these and other risks based on their own practice and to re-evaluate their risk estimates as
they gain familiarity with FFF. These risks should also be put into the context of radiotherapy
delivery with flattened beams. Ideally, risks associated with use of FFF beams would be part
of a comprehensive departmental risk analysis, but an analysis of special potential risks of FFF
treatments is an efficient way to get started.
An institution’s radiotherapy program should be tailored based on such an FMEA analysis.
For example, if skin dose is a concern, detailed measurements could be conducted or treatment
planning policies could be enacted to ensure beams are broadly spread out over the patient. If
QA device performance at high-dose rates is uncertain, a detailed comparison of the QA device
to a dose-rate independent standard should be conducted. This analysis may also drive additions
to an institution’s periodic QA program. Of note, end-to-end testing is critical to increasing
the detectability of many problems, particularly beam type selection errors and dosimetric
problems, such as low MU segments.
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Table 3. Example FMEA analysis of beam delivery unique to FFF. Per TG-100, a 1–10 scale is used, where Occurrence
(O) ranges from 1 (almost impossible) to 10 (almost inevitable), Severity (S) ranges from 1 (minor annoyance) to 10
(lethal), and Detectability (D) ranges from 1 (highly detectable) through 10 (almost impossible to detect until it causes
patient harm). The product of O, S, and D denotes the relative risk of that failure mode. Values presented in the table
are suggestions only, pooled from authors on this report.
					
Risk Probability
					 Number
Failure Mode
O
S
D
(product)
Inaccurate calibration (e.g., error in Pion)

2

5

6

60

Failure to account for excessive skin dose

5

6

4

120

Dose problems from low MU segments

3

4

4

48

Inaccuracy of QA devices

4

5

4

80

Wrong beam type selection due to confusing user
interface in planning

3

4

4

48

Wrong beam type selection due to confusing user
interface in delivery

2

6

3

36

Wrong beam type selection due to incorrect transfer
from TPS and/or R&V

2

6

2

24

Use of wedges or other devices for which FFF
wasn’t commissioned

2

6

4

48

Failure to catch problem during treatment due to
fast delivery

3

5

5

75

Calibration error due to chamber placement off-axis

2

5

6

60

H. Facility planning
H.1 Workload estimates
Workload (total administered dose per week) could differ between flattened and FFF machines if
the machine is used for a different application (particularly dedicated stereotactic use). However,
for most clinical scenarios, patient throughput, and therefore workload, is unlikely to increase
with the FFF mode because the bulk of treatment time is not beam-on time. Naturally, this will
be determined by clinical needs and distribution of machine resources.
H.2 Vault barriers
For Varian linacs, where the energy is not restored, primary barrier thickness is 10%–20% less
for FFF beams, compared with flattened beams, because of the decreased transmission associated with its softer photon spectrum.(73) Secondary barrier thicknesses are also 10%–20% less
for FFF beams, compared with flattened beams. This is in part because of decreased and lower
energy patient scattered radiation exiting the patient/phantom at most angles. Secondary barrier
thickness is also less for FFF beams because of decreased head leakage levels. Only one-half
(6 MV) to one-quarter (18 MV) as much head leakage occurs with FFF-based treatments as
compared to flattened beam treatments.(73) This is particularly important for IMRT applications
where head leakage plays a major role in vault shielding.
For machines with energy-restored FFF beams, there is still a shielding benefit, although
it is slightly less. Primary barrier thickness was found to be up to 8% less, while secondary
barriers were found to be up to 11% less.(74)
Radiation survey results have confirmed lower doses associated with the FFF modality.(74,75)
H.3 Neutrons
Neutrons are generally a concern only for energies above 10 MV; currently, only Siemens linear
accelerators have such FFF beams.
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The neutron spectrum is essentially constant, regardless of the presence of a flattening
filter.(76,77) Consequently, neutron shielding requirements scale directly with fluence, which is
substantially reduced with FFF beams.(76-78) This is primarily due to the increased efficiency
of photon delivery — fewer photons are generated to deliver the same dose to the patient, so
correspondingly fewer photoneutrons are created. To a much smaller degree, reduction in the
neutron fluence also occurs because the flattening filter is no longer a source of neutrons (the
flattening filter produces ~ 10% of neutrons in a high-energy (18–24 MV) Varian linac(76,79)
and < 1% in a 15 MV Siemens beam(80)).
Neutron shielding values of source strength (Q) and dose equivalent (H0) for FFF beams are
nearly 80% lower (per photon Gy at dmax for an 18 MV Varian linac).(76) In cases with beam
modulation, the neutron source strength and dose equivalent must be scaled by the modulation, which for clinical treatments corresponds to an approximately 70% reduction in neutron
fluence and dose equivalent.(78)
In addition to the decreased shielding burden, the decreased neutron fluence also corresponds
to a decreased personnel dose through room activation.(75)
In short, neutrons are at most a minimal issue, even for high-energy FFF beams.
H.4 Recommendations: Facility planning and radiation safety
From a facility planning and radiation safety perspective, FFF beams are superior to flattened ones in that there is a smaller shielding burden for the FFF mode. However, current
FFF beams are offered in conjunction with flattened beams, requiring shielding of those flattened beams, as well. Therefore, unless the FFF mode is intended to be predominantly used,
shielding for the traditional flattened beams is likely optimal, offering prudent shielding for
all machine applications.
IV. THEORETICAL ISSUES
A. Radiobiological aspects
The dose-rate differences between treatments delivered by conventional beams (~ 3–6 Gy/min)
and by FFF ( ~ 15–30 Gy/min) have prompted some new investigations,(81-87) and a second look
at experimental studies of earlier decades.(88-96) The dose rates that are usually quoted for both
conventional and FFF (see Table 1) are averages, as dose is delivered in ~ 2 μs wide pulses
with instantaneous dmax dose rates of approximately 1.7 × 102 Gy/s for conventional beams and
approximately 7 × 102 Gy/s for FFF. According to theoretical estimates(94) and early radiobiology
experiments,(83,96,97) FFF instantaneous dose rates are not expected to be high enough to affect
cell survival through changes in the basic radiochemistry of radical recombination.
It has been suggested that shorter total treatment times may result in less sublethal damage
repair and thus more efficient tumorcidal effects, but also more risk of normal tissue damage(81)
or conversely, that treatments of longer duration are less tumorcidally efficient.(82,94-87) A few
studies have evaluated cell survival in vitro in FFF beams, but with differing results.(98,99)
Clinically, FFF beams are just one means of reducing fraction delivery time — and FFF
on its own does not necessarily lead to the most drastic decreases in total delivery time. The
anticipated treatment delivery time difference between FFF and flattened beams is often less than
the difference between IMRT and conventional therapies, or between IMRT and modulated arc
therapy (VMAT) therapies. Additional confounding effects that may accompany reduction of
treatment time in clinical studies include such things as improved positioning accuracy and the
frequent combination of FFF with sophisticated image guidance — both of which should tend
to improve local control on their own. The basic radiobiology of increased dose rate is certainly
a subject of academic interest, and interested readers may wish to consult the references of this
section, as well as additional sources.(93,100,101) But it is unlikely that the question of whether the
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radiobiology of the dose-rate increase in FFF beams can change clinical outcomes can be unraveled from the ‘noise’ of the many other variables present in typical clinical outcomes studies.
V. FUTURE NEEDS
Although extensive work has been done in many areas of study regarding FFF beams, research
is still needed.
Dosimetry questions may arise, as many detectors (including ion chambers) are dose-rate
dependent and, therefore, may need different correction factors for FFF beams in order to
achieve precision dosimetry.
For many of these issues, the impact of changing the primary beam energy requires attention. Most of the studies in the literature have used the same electron energy incident on the
target for both flattened and FFF versions of the beam. The consequent softer photon spectrum
produces, among other phenomena, a more shallow dmax, increased skin dose, and increased
patient scatter. With the Siemens and Elekta implementation, the accelerating potential of the
FFF beam is increased to restore the PDD. This may restore dmax to a corresponding flattened
beam level, but other factors such as skin dose and patient scatter require further study. Readers
of the literature must pay particular attention to the electron accelerating potential of the study
they are reading. Clearer delineation of photon beam properties as a function of electron energy
is necessary for FFF studies.
Skin dosimetry, its dependence on treatment parameters, and skin doses in clinical treatments, requires further study. It has, to date, typically been assessed at a relatively deep depth,
below where sensitive skin layers are generally assessed. The impact of treatment parameters
also requires additional study.
The role of FFF beams in radiotherapy would also be more clearly defined with further study
on intrafractional motion and its possible interplay with MLC and gantry motion.
Clinical issues also need additional evaluation. Although FFF beams have been shown to
be suitable for essentially all IMRT situations evaluated, is there a subset of clinical cases for
which FFF IMRT is optimal? Additionally, for conventional therapy, is there a simple way to
deliver flat fields without developing an inverse planned solution?
Finally, radiobiological issues remain somewhat unresolved. Although different dose rates
are unlikely to be relevant in terms of basic chemistry, cell repair mechanisms may be affected.
This could impact both tumor control and normal tissue toxicity, although the clinical ramifications of this remain unclear, particularly in the context of 3D CRT versus IMRT versus VMAT,
where treatment times also vary substantially.
Despite the unanswered questions, FFF technology has been adopted rapidly and recommendations are, therefore, provided in this document. Refinements to this technology and to
clinical recommendations will no doubt occur as this technology matures.
VI. RECOMMENDATIONS
Acceptance Testing (II.B)
1. Prior to measurements, evaluate dose rate dependence of measurement devices.
2. Follow guidelines of TG-45 and TG-142 except that, for flatness, measure beam profile for
conformance to specs.
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Commissioning (II.C)
1. Calibration: Follow standard calibration protocol (e.g., TG-51) but account for beam differences (II.C.1):
Determine kQ per protocol, but expect a slightly different value.
Determine Pion with two-voltage technique, but verify validity of this approach.
Center the chamber, especially for higher energies.
Correct for partial volume averaging or use a smaller chamber.
2. General beam data (II.C.2):
Evaluate variation of scanning chamber Pion for off-axis positions.
Follow recommendations of TG106.
3. Conduct end-to-end testing of the system (II.C.3).
Periodic QA (II.D)
1. Follow guidelines of TG-142, looking at profile consistency over time.
2. Test all QA measuring devices for dose-rate characteristics.
Treatment Planning
1. Make sure your TPS is able to handle FFF beams (II.E).
2. In view of the uncertainties (both measurement and TPS calculation) regarding FFF skin
doses, use beam arrangements that spread out the skin dose (II.C.2).
3. Before clinical use at a specific disease site, do comparative planning for several cases to
assess the plan quality with flattened vs. FFF beams for the same case (III.B, III.C).
Safety
1. Construct an FMEA table to evaluate the risk of failure modes and test modes that are of
most concern (III.G).
2. Verify R&V support for FFF beams (II.C.3).
Facility planning (III.H)
1. Existing vaults for same nominal energy are adequate.
2. New vaults with mixed flattened and FFF use, either use traditional (flattened) shielding
(conservative), or reduced shielding if FFF use is expected to be substantial.
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